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Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Not only burdened by the limited overall survival, lung 
cancer patient also suffer from various symptoms, such as pain, that implicated in the quality of life. Cancer pain is a complicated 
and transiently dynamic symptom that results from multiple mechanisms. This review will describe the pathophysiology of cancer 
pain and general approach in managing a patient with lung cancer pain. The use of opioids, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and adjuvant analgesia, as part of the pharmacology therapy along with interventional strategy, will also be discussed. 
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Introduction
Pain influenced the total quality of life signi-
ficantly; unfortunately, pain is under-assessed 
and undertreated globally. Chronic pain is one of 
the main problems in cancer survivor population 
and prevalence varies between 16% and 50% [1]. 
In meta-analysis report, prevalence of pain was 
> 50% among six type of cancers; head and neck 
cancer 70%, gynecological cancer 60%, gastro-
intestinal cancer 59%, lung cancer 55%, breast 
cancer 54%, and urogenital cancer 52% [2]. Among 
patient with advanced metastatic stage including 
lung cancer, the prevalence even reached about 
75−90% [3]. Pain is also among the common symp-
toms that could bring lung cancer patient to search 
for medical care [4]. The severity of chronic can-
cer-related pain is associated with shorter survival 
in advanced non-small cell lung cancer (NSCLC), 
independently of known prognostic factors [5].
Definitions
Pain is an unpleasant sensory and emotional 
experience that is associated with actual or po-
tential tissue damage or described in such terms 
[6]. There are three main types of pain: somatic 
(nociceptive) pain, visceral pain, and neuropathic 
pain. Somatic pain is the most common type of 
pain in patients with cancer, and is characteri-
zed as well localized, intermittent, or constant 
and described as aching, gnawing, throbbing, or 
cramping [7]. Visceral pain usually occurs when 
lung cancer metastases to the intra-abdominal 
organ [8]. Neuropathic pain is pain that arises as 
a direct consequence of a lesion or diseases affec-
ting the somatosensory system [9]. Neuropathic 
pain can affect up to 40% in patients with cancer, 
which could be related to the tumor, treatment or 
comorbid diseases [10]. Breakthrough pain (BTP), 
is defined as transitory, severe flares of pain that 
occur in opioid-treated patients with chronic 
background pain [11, 12]. Pain associated with 
lung cancer is characterized by multiple expres-
sions, due to either the progression of the disease 
and/or induced by oncological treatment [13]. 
Refractory pain, or intractable pain, is defined as 
not responding to standard treatments [14]. Po-
st-thoracotomy pain syndrome (PTPS) is defined 
as pain that recurs or persists along a  thoraco-
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tomy incision at least two months following the 
surgical procedure [15, 16]. The most frequently 
used standardized scales to assess pain are visual 
analog scales (VAS), a verbal rating scale (VRS) 
and a numerical rating scale (NRS) [17].
Risk factors
Sociodemographic status, health status, and 
depression were associated with severity of pain 
in lung cancer [18]. Moreover, younger age, lower 
perceived health status and higher levels of other 
cancer symptoms (fatigue, shortness of breath and 
difficulty eating) were also significantly associa-
ted with a higher likelihood of reporting moderate 
to severe lung cancer pain [19]. Among lung can-
cer patients, current smokers reported pain and 
receiving pain treatment more often than former 
smokers [20]. The coping style has also been re-
ported to affect pain. In one report, the repressive 
group showed statistically significant lower mean 
scores for pain quality and pain catastrophizing 
compared to the low-anxious group, high-anxious 
group and defensive high-anxious [21]. Genetic 
variations study revealed that interleukin (IL)-8-
T251A were the most relevant genetic factor for 
lung cancer pain [22, 23].
Pathophysiology 
The neurophysiology of cancer pain involves 
inflammatory, neuropathic, ischemic and com-
pression mechanisms at multiple sites, and 
knowledge of these mechanisms and the ability 
to decide whether a pain is nociceptive, neuropa-
thic, and visceral or a combination of all three will 
lead to best practice in pain management [24]. 
Many of the same inflammatory factors that pro-
mote tumor growth, such as TNFa and NF-kB, 
are also function as pain modulators [25]. These 
putative mediators subsequently sensitize and ac-
tivate primary afferent nociceptors in the cancer 
microenvironment [26]. Nociceptive pain was the 
major pathophysiological subtype in lung cancer 
pain, but neuropathic pain accounted for 30% 
(range 25−32%) of cases [27]. Cytokines associa-
ted with inflammation or tissue damage due to 
tumor growth and spreads have been thought to 
contribute to pain hypersensitivity by modifying 
the activity of nociceptors [28]. Furthermore, 
tumors growing in the vicinity of peripheral 
nerves can compromise the integrity of the nerve, 
inducing a neuropathic condition accompanied 
by persistent pain, hyperalgesia, or allodynia [29]. 
Other mediators that have been studied to be 
involved in the cancer-related pain are nerve 
growth hormone [30, 31], bradykinin [32−34], en-
dothelin-1 [35, 36], proteases-activated receptor 2 
(PAR2) [37, 38], proton and acid-sensing receptor 
[39, 40]. Carriers of the specific IL-6 (i.e. IL-6-
174C/C) genotypes required 4.7 times higher dose 
of opioids for pain relief compared with other 
genotypes [41]. Persistent idiopathic facial pain 
associated with mediastinal involvement in non
-small cell lung cancer (NSCLC) may occur at pre-
sentation or at relapse [42]. Lung cancers rarely 
metastasize to the spleen, however if it is the case, 
the patient could suffer abdominal pain [43, 44]. 
Patients who undergo thoracotomy for lung can-
cer also have been reported to experience ipsila-
teral shoulder pain [45].
General approach in cancer pain management
Medical professionals’ practices and know-
ledge regarding cancer pain management have 
been said as inadequate, especially due to differen-
ces between physicians and nurses in knowledge 
and practices for cancer pain management [46]. 
Effective communication is needed for optimal 
cancer pain management [47]. Open commu-
nication and disclosure also played important 
roles in the appraisal of pain symptoms [48]. 
Lung cancer patient who continues to smoke 
should be motivated intensively to quite in order 
to reduce the level of pain [19]. In general, the 
following aspect should be taken into considera-
tion: (1) the medication regimen should be kept 
as simple as possible to avoid further side effect 
and cost burden; (2) the oral route of admini-
stration is preferred, and if is not possible, rectal 
or transdermal delivery is often feasible; and (3) 
for parenterally administered medication, the 
intravenous or subcutaneous routes should be 
used because intramuscular administration has 
the disadvantages of increased pain with admini-
stration and unpredictable absorption [49].
The mainstay of cancer pain management is 
systemic pharmacotherapy [50]. The World He-
alth Organization (WHO) has developed a 3-step 
pain ladder to help the health care professional 
effectively manage pain, classifying pain intensity 
according to severity and recommending analge-
sic agents based on their strength [51]. In step 1, 
pain can be managed with nonsteroidal anti- 
-inflammatory drugs (NSAIDS) and other non- 
-opioid analgesics [52]. If pain persists or incre-
ases, step 2 requires opioids for mild to moderate 
pain along with NSAIDS and non-opioid analgesics 
[53]. Step 3 of the ladder is applicable to many can-
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cer pain syndromes and includes opioids for mo-
derate to severe pain in conjunction with NSAIDS 
and non-opioids [54]. Appropriate pain treatments 
in cancer include opiates, adjuvant medications, 
nerve blocks, and nondrug interventions [55]. 
Lung cancer pain management
Opioids
The second step of the WHO analgesic ladder 
comprises opioid analgesics such as tramadol, 
codeine, dihydrocodeine, and dextropropoxy-
phene [56]. Morphine activates the μ-opioid 
receptors, resulting in not only analgesia and se-
dation, but also euphoria, respiratory depression, 
constipation, and pruritus [57]. An opioid recep-
tor is significantly implicated in anti-nociceptive 
processes and is found to be represented in the 
regions involved in nociception and pain [58]. 
All opioids are effective in controlling cancer pain 
and there is no proof that one opioid is better than 
another one [59]. However in poorly responsive 
patients, it is possible to do rotation from one 
drug to another [60]. Opioid rotation is a thera-
peutic maneuver aiming in improving analgesic 
response and/or reducing adverse effects, including 
a change to different medication using the same ad-
ministration route, maintaining the current medica-
tion but altering administration route, or both [61]. 
Opioids could be administered through oral, tran-
sdermal, intravenous, subcutaneous, rectal, or 
intraspinal [62]. Opioids are normally admini-
strated at relatively low dose initially, and the 
dose is increased only if the pain is unchanged or 
increased during next pain level assessment [63]. 
In acute exacerbation of pain (i.e. BTP), fenta-
nyl buccal tablet (FBT) provides a rapid onset of 
analgesia (10−15 minutes) by enhancing fentanyl 
absorption across the buccal mucosa [64]. For conti-
nuous chronic pain, opioids should be administered 
around-the-clock and several long-acting formula-
tions are available that require administration only 
once or twice daily [65]. For example, transdermal 
fentanyl, common controlled-release transdermal 
formulations, combines a strong opioid with a 72-
hour release profile and the benefits of a parenteral 
route, avoiding the first-pass metabolism [66]. 
Cancer patients received a significantly hi-
gher cumulative opioid dose compared with 
dementia and chronic obstructive pulmonary 
disease patients [67]. Various clinical studies 
demonstrated tramadol analgesia and acceptable 
toxicity in patients with cancer pain [68]. Lung 
cancer patients enrolled in the European Pharma-
cogenetic Opioid Study (EPOS) received opioids 
varied from 10 to 5072 mg (mean 414, median 175) 
however only minority of patients achieved com-
plete pain relief [69].
The use of opioid in lung cancer pain is not 
without problems. Preclinical studies have de-
monstrated that opioid receptor agonists increase 
the rate of non-small cell lung cancer (NSCLC) 
growth and metastasis [70]. Opioid receptor 
expression was increased significantly in cancer 
samples from patients with lung cancer compared 
with adjacent control tissue [71]. From in vitro 
study, opioid receptor regulates growth factor 
receptor signaling and epithelial-mesenchymal 
transition (EMT) in human NSCLC cells that is 
required for cells proliferation and migration [72]. 
Intraoperative opioid use is associated with de-
creased overall survival (OS) in stage I but not 
stage II-III NSCLC patients [73]. There has been 
an association between increased doses of opioids 
during the initial 96 hours postoperative period 
with a higher recurrence rate of NSCLC within 
5 years which could be related to suppression 
of natural killer cells by opioid analgesics [74]. 
However, a study from single institution recently 
revealed that opioids were found to have no ne-
gative influence on survival time [75]. Moreover, 
morphine showed a beneficial effect on dyspnea 
in terminally ill lung cancer patients [76]. 
Non-opioid drugs
Anti-inflammatory drugs such as acetamino-
phen/paracetamol and nonsteroidal anti-inflam-
matory drugs (NSAIDs) could be used for mild 
cancer pain, and although adding a NSAID to an 
opioid for stronger cancer pain is efficacious, but 
the risk of long-term adverse effects has not been 
quantified [77]. One finding showed there is in-
sufficient data to support the addition of NSAIDs 
to WHO Step III opioids to improve analgesia or 
to reduce opioid dose requirement [53].
Adjuvant analgesics
Adjuvant analgesics are defined as drugs 
with a primary indication other than pain that 
have analgesic properties in some painful con-
ditions [78]. These type of drug were classified 
as: (a) multipurpose adjuvant analgesics such as 
antidepressants, corticosteroids, a2-adrenergic 
agonists, neuroleptics, (b) neuropathic pain such 
as anticonvulsants, local anesthetics, N-methy-
l-D-aspartate receptor antagonists, (c) bone pain 
(calcitonin, bisphosphonates, radiopharmaceuti-
cals), (d) musculoskeletal pain (muscle relaxants), 
or pain from bowel obstruction (octreotide, anti-
cholinergics) [78]. For the first line of neuropathic 
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pain, the National Institute for Health and Care 
Excellence (NICE) recommends amitriptyline, 
duloxetine, gabapentin or pregabalin as initial 
treatment for neuropathic pain [79].
Interventional options
Although the use of oral analgesics for the 
control of cancer pain has been demonstrated to 
be successful in most patients, some patients will 
fail to respond to pharmacological therapy or will 
suffer unacceptable adverse effects [80]. Several 
intervention strategies have been studied with 
various efficacies, such as neuraxial infusion, 
paravertebral blocks, and cordotomy [81]. Indica-
tions for neuraxial infusion include pain refrac-
tory to systemic opioids after trials of dose esca-
lation and/or opioid rotation and the occurrence 
of unacceptable side effects [82]. Paravertebral 
blocks usually performed for post-thoracic surge-
ry analgesia [83]. For lung cancer located in the 
apex, known as the Pancoast tumor, it can cause 
pain due to compression of the brachial plexus. 
The addition of paravertebral cervical nerve block 
could relieve the lung cancer (Pancoast tumor) 
patient from pain [84]. The target of computed 
tomography (CT)-guided percutaneous cordotomy 
is the lateral spinothalamic tract located in the an-
terolateral region of the spinal cord at the C1-C2 
level [85, 86]. CT-guided percutaneous cordotomy 
has been shown to provide sufficient pain relieve 
among lung cancer patient, including Pancoast 
tumor, and mesothelioma [87−90]. Lastly, there 
are insufficient data to say whether acupuncture 
is effective in treating cancer pain in adults [91]. 
Role of radiotherapy in reducing pain in lung cancer
Radiation was indicated in the palliation of 
hemoptysis, chest pain, dysphagia, and dyspnea in 
a patient with lung cancer [92]. A randomized trial 
showed palliative radiotherapy of 17 Gy mid-point 
dose in two fractions 1 week apart does relieve 
chest pain in lung cancer pain [93]. Generally, 
a significant number of patients achieved complete 
resolution of symptoms and palliation of chest pain 
with the fractionated regimen of radiotherapy [94]. 
However, radiotherapy was found to be ineffective 
for reducing morphine dose in patients with bone 
metastasis from lung cancer [95].
Conclusion
Pain affects the majority of lung cancer pa-
tient and, if it’s left under-treated, it will implicate 
in the significant reduction of quality of life. Lung 
cancer pain could be a nociceptive pain, visceral 
pain, or neuropathic pain. General approach in 
managing lung cancer pain follows the WHO pain 
ladder strategy. Despite its disadvantage in the 
increased incidence of recurrence, opioid remain 
the mainstay of lung cancer treatment. Interven-
tional options serves as the alternative strategy 
if the optimal dose of opioid failed to relieve the 
patient from pain. 
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